首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   348篇
  免费   12篇
儿科学   1篇
妇产科学   1篇
基础医学   29篇
口腔科学   2篇
临床医学   14篇
内科学   195篇
皮肤病学   3篇
神经病学   21篇
特种医学   5篇
外科学   8篇
综合类   4篇
预防医学   31篇
药学   33篇
中国医学   1篇
肿瘤学   12篇
  2022年   3篇
  2021年   8篇
  2020年   3篇
  2019年   10篇
  2018年   6篇
  2017年   4篇
  2016年   3篇
  2015年   2篇
  2014年   4篇
  2013年   3篇
  2012年   12篇
  2011年   19篇
  2010年   11篇
  2009年   11篇
  2008年   19篇
  2007年   11篇
  2006年   18篇
  2005年   15篇
  2004年   19篇
  2003年   15篇
  2002年   13篇
  2001年   18篇
  2000年   17篇
  1999年   10篇
  1998年   7篇
  1995年   5篇
  1994年   4篇
  1993年   2篇
  1992年   3篇
  1991年   4篇
  1990年   7篇
  1989年   3篇
  1988年   4篇
  1986年   5篇
  1985年   4篇
  1984年   3篇
  1983年   6篇
  1981年   3篇
  1980年   2篇
  1979年   3篇
  1978年   9篇
  1977年   2篇
  1976年   5篇
  1974年   2篇
  1973年   4篇
  1972年   4篇
  1971年   3篇
  1970年   3篇
  1962年   1篇
  1961年   1篇
排序方式: 共有360条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Tegaserod does not alter fasting or meal-induced biliary tract motility   总被引:1,自引:0,他引:1  
OBJECTIVE: Tegaserod is a 5-HT(4) receptor partial agonist that increases peristaltic activity of the intestinal tract. It is approved for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). IBS is a chronic gastrointestinal disorder of function that is reported to be associated with an increased incidence of abdominal surgery including cholecystectomy. The effect of tegaserod on nongut digestive organs, such as the gallbladder and biliary tract, has not been previously investigated. Therefore, this study aimed to evaluate the effects of tegaserod on gallbladder contractility and on functional status of the sphincter of Oddi during both the interdigestive and the digestive periods in healthy female subjects and in female patients with IBS-C. METHODS: During a 6-wk, double-blind, placebo-controlled crossover study, gallbladder contractility and concomitant change in luminal diameter of the common hepatic duct (CHD) and the common bile duct (CBD, both proximal and distal) in response to a standard liquid meal were quantified using real-time ultrasonography. Changes in luminal diameter of the CHD and the CBD were used as a surrogate marker for sphincter of Oddi function. Ultrasound measurements were conducted every 15 min from 45 min before, to 60 min after the test meal to observe the impact of tegaserod on gallbladder volume and any concomitant change in the diameters of the CHD and the CBD that developed in response to gallbladder contraction. The ultrasound measurements of gallbladder contractility, along with the CHD and the CBD diameters, were repeated after each of the two 2-wk periods of treatment with tegaserod or placebo. The recommended dose of tegaserod (6 mg b.i.d.) for IBS-C patients was used in healthy female subjects (n = 13) and female patients with IBS-C (n = 20). Twice this dose (12 mg b.i.d.) was also evaluated in an additional 20 female patients with IBS-C. Statistical evaluations were conducted using a two-sided analysis of variance (ANOVA). RESULTS: Gallbladder contractility variables including ejection fraction, ejection rate and ejection period, fasting and residual volume, and maximal emptying, were similar after 2 wk of treatment with tegaserod 6 mg b.i.d. and placebo in healthy female subjects and female patients with IBS-C. There were no significant changes in the luminal diameters of the CHD or the CBD after tegaserod compared to placebo in any cohort. Additionally, no significant dilation (> or =7 mm in diameter) of the CHD or CBD was observed during maximal gallbladder emptying. Similar results were also observed when tegaserod was given at 12 mg b.i.d. in patients with IBS-C. Tegaserod treatment had no significant effect on plasma CCK concentration in response to the test meal. No significant abdominal pain or unexpected adverse events were reported during the study. CONCLUSIONS: This study showed no significant pharmacodynamic effect of tegaserod on gallbladder contractility or on CBD and CHD diameters as a surrogate marker of sphincter of Oddi function during both the interdigestive (fasting) and the digestive (postprandial) periods in healthy female subjects and female patients with IBS-C.  相似文献   
5.
BACKGROUND: Pre-medication with droperidol has been used to improve sedation during endoscopy, especially in patients with a history of alcohol or narcotic abuse. We studied whether routine use of droperidol pre-endoscopic retrograde cholangiopancreatography (ERCP) could improve patient and physician satisfaction with sedation. METHODS: Sixty-seven patients undergoing routine ERCP were enrolled in this double-blind placebo-controlled study. Patients were given either parenteral normal saline solution or 5 mg of droperidol 15 minutes before the procedure. After the ERCP, several parameters of procedural sedation were scored on an ordinal scale by the endoscopist, the endoscopy nurse, and the recovered patient. In addition, a follow-up telephone call was made to the patient after 24 hours. RESULTS: The mean procedural room time was similar in the two groups. Nearly 25% less meperidine and diazepam was used in the droperidol-treated patients, making the overall medication cost similar in both groups. The mean recovery room time was 113 minutes for the placebo group and 106 minutes for the droperidol group. Droperidol premedication significantly decreased post-procedure nausea and vomiting, reduced gagging at intubation, and decreased retching during the procedure. Droperidol also improved physician (p = 0.001), nurse (p = 0.001), and patient (p = 0.0001) impressions of overall sedation and decreased the need for physical restraint during the procedure. Droperidol significantly increased the number of patients with no memory of the procedure. CONCLUSION: Droperidol improved overall patient, physician, and nurse satisfaction with sedation during ERCP. It also reduced post-ERCP nausea and vomiting without increasing recovery time or medication cost. Droperidol is recommended for routine pre-ERCP sedation. (Gastrointest Endosc 2000;52:362-6).  相似文献   
6.
We report a case of multiple duodenal ulcers with gastric hypersecretion due to a nongastrin secretagogue produced by a malignant tumor of the pancreas in a 78-year-old man. The case resembled a Zollinger-Ellison syndrome (ZES) with high acid output (basal acid output 27, sham meal-stimulated 37, maximum acid output 47 mEq/h), but with fasting gastrin 43 pg/ml, nonresponsive to secretin. As in ZES, pepsin output was comparatively low, and secretion was inhibitable by atropine (50% inhibited by 1 microM). The tumor removed at surgery contained less than 1 ng gastrin per gram, but was many times more potent than pentagastrin in stimulating acid from a lumen-perfused rat stomach. The tumor also contained cholecystokinin (CCK-8 and CCK-33), motilin, insulin, and somatostatin, which were also present in adjacent normal pancreas; in addition, the tumor contained pancreatic polypeptide and pancreatic cancer-associated antigen. This case represents a rare syndrome due to an as yet undefined peptide secreted by a (frequently malignant) pancreatic endocrine tumor and masquerading as ZES. This is the first report of studies of pepsin secretion and of the effect of atropine, suggesting that the physiologic effects of the secretagogue resemble that of gastrin.  相似文献   
7.
An isolatedex vivo perfused mammalian stomach preparation is an ideal model for the study of motility avoiding central nervous influence and circulating humoral factors. In this paper, we describe the technique of such preparation in two different species: rat and cat, and its implication for motility study. While the isolated stomach was perfused with Krebs-Ringer solution via celiac artery, motility of the antrum was recorded using an open-tip tube in rats and a bipolar platinum electrode and a strain gauge in cats. The spontaneous antral motility and its response to drugs, such as dopamine and domperidone proved that the preparation would be a useful model to study motility devoid of influences of the central nervous system and circulating humoral agents.Dr. S.K. Odaibo was supported by a special postdoctoral clinical research fellowship award PG/256/168 from the University of Ilorin, Ilorin, Nigeria.Presented in part at the American Gastroenterological Association Meeting, Washington, DC, May 1983.  相似文献   
8.
9.
This study established norms and examined validity and reliability of the recently developed Korean version of the Dementia Rating Scale (K-DRS; Chey, 1998) for the elderly Korean population. The K-DRS was administered to 148 normal elderly Korean people and 20 patients with dementia of the Alzheimer's type (DAT). Norms were developed a priori for two age groups (55–64 and 65–84 years). Education (p < .0001) and age (p < .05) proved significant factors in the performance of the K-DRS, whereas gender did not. Accordingly, norms were further specified into two educational levels (6 years or fewer, and more than 6 years). Education was recognized as an important factor in evaluating dementia in a population with limited education. These implications are significant for dementia studies done in developing countries where educational opportunities have been limited for elderly people. Evidence supporting the validity and reliability of the scale was also found. K-DRS total scores correlated well with diagnostic status (r >pb> =.63) and mental status exam scores (r =.80). Test-retest reliability was .96, and interrater reliability was .99.  相似文献   
10.
This case details the development of a rapidly growing polypoid mass in the proximal stomach in a patient with known attenuated familial adenomatous polyposis. Surgical resection was required and histology showed hyperplasia with extensive areas of dysplastic adenomatous change. This case illustrates that patients with the attenuated form of familial adenomatous polyposis are at risk for multiple neoplasia distinct from those patients with the classic form of familial adenomatous polyposis.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号